Recent data from Regeneron and Eli Lilly on their antibody drugs for COVID-19 show promise in their use for non-hospitalized patients. “The real use and benefit [of the antibody drugs] will be preventing people from going into the hospital,” CP3 Director Walid Gellad told Politico's Prescription Pulse.